FTSE 100 news / Companies and sectors / AstraZeneca / AstraZeneca completes $2bn Summit Therapeutics investment
AstraZeneca completes $2bn Summit Therapeutics investment
+5.0 positive
AstraZeneca, Daiichi Sankyo and Summit announced a trial collaboration combining Datroway with ivonescimab, alongside AZ's $2bn Summit investment.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| AD HOC NEWS | 6 | +4.2 |
| TradingView | 6 | +2.9 |
| Kalkine Media | 5 | +3.4 |
| TipRanks | 4 | +6.7 |
| geneonline.com | 4 | +3.8 |
| Yahoo Finance | 3 | +7.2 |
| Traders Union | 3 | +6.4 |
| Simply Wall Street | 3 | +4.4 |
| finance.biggo.com | 2 | +6.3 |
| Indian Pharma Post | 2 | +6.0 |
| The Business Journals | 2 | +5.0 |
| Quiver Quantitative | 2 | +4.2 |
| Stocktwits | 2 | +4.2 |
| Oncodaily | 2 | +4.2 |
| Investing.com | 2 | +2.1 |
| Proactive Investors UK | 1 | +9.2 |
| insights.citeline.com | 1 | +8.3 |
| WSJ | 1 | +8.3 |
| MarketScreener | 1 | +7.5 |
| europeanpharmaceuticalreview.com | 1 | +7.5 |
| Pharmaceutical Technology | 1 | +7.0 |
| BioPharm International | 1 | +7.0 |
| benzinga.com | 1 | +7.0 |
| AllSci | 1 | +7.0 |
| PMLiVE | 1 | +6.7 |
| CNBC | 1 | +6.7 |
| AskTraders | 1 | +6.7 |
| contractpharma.com | 1 | +6.7 |
| app.dealroom.co | 1 | +6.7 |
| finchannel | 1 | +6.3 |
| citybiz | 1 | +6.3 |
| Pluang | 1 | +6.3 |
| Medical Dialogues | 1 | +6.3 |
| Endpoints News | 1 | +6.3 |
| The Pharma Letter | 1 | +6.3 |
| Stock Titan | 1 | +6.3 |
| StreetInsider | 1 | +6.3 |
| Mugglehead Investment Magazine | 1 | +6.3 |
| Chemical Industry Digest | 1 | +5.8 |
| GeneOnline | 1 | +5.8 |
| Biostock | 1 | +5.8 |
| Fierce Pharma | 1 | +5.8 |
| European Biotechnology Magazine | 1 | +5.8 |
| businesswire.com | 1 | +5.3 |
| Quartz | 1 | +5.0 |
| pharmexec.com | 1 | +5.0 |
| kalkinemedia.com | 1 | +5.0 |
| stocktitan.net | 1 | +5.0 |
| 24/7 Wall St. | 1 | +5.0 |
| BioSpace | 1 | +5.0 |
| This is Money | 1 | +5.0 |
| BioWorld News | 1 | +5.0 |
| bioxconomy.com | 1 | +4.2 |
| FirstWord | 1 | +4.2 |
| MedCity News | 1 | +3.3 |
| Investor's Business Daily | 1 | +3.3 |
| timothysykes.com | 1 | +3.3 |
| tradersunion.com | 1 | +3.3 |
| Insider Monkey | 1 | +3.0 |
| AKM.RU | 1 | +2.5 |
| Yahoo Finance UK | 1 | +1.7 |
| FirstWord Pharma | 1 | +1.7 |
| Barchart.com | 1 | −4.2 |
Day by day
Monday 12 October 2026
Reports say Summit secured the $2bn AstraZeneca investment, with a recap on funding ivonescimab.
- +5.0 Summit secures $2 billion AstraZeneca investment
Large $2 billion investment in Summit supports oncology pipeline. - +4.2 Weekly Recap: U.S. $50B expansion and Summit stake funding ivonescimab
US expansion and Summit stake funding ivonescimab development.
Saturday 10 October 2026
Coverage looks at the Summit investment, with shares edging lower and the CEO highlighting the drug's potential.
- +5.8 AstraZeneca CEO Highlights Summit Drug’s Potential in Cancer Treatment
CEO highlights potential of Summit cancer drug, linked to AstraZeneca investment. - −3.3 Why Are AstraZeneca (LSE:AZN) Shares Edging Lower After The Summit Therapeutics Investment Today?
Shares edging lower after Summit Therapeutics investment.
Friday 9 October 2026
AstraZeneca completed its $2bn Summit investment and shares rallied.
- +6.7 AZN rallies as Summit Therapeutics investment completes
Shares rallied as Summit investment completed - +5.8 AstraZeneca Executes $2B Summit Investment to Advance Bispecific ADC Cancer Combos
$2B Summit investment to advance bispecific ADC combinations
Thursday 8 October 2026
Coverage of AstraZeneca's Summit Therapeutics investment and collaboration continues.
- +6.7 AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
Collaboration with Daiichi Sankyo and Summit - +6.7 AstraZeneca (LSE:AZN) Summit Therapeutics Investment Deepens Its Cancer Pipeline While FTSE 100 Trades Higher
Summit investment deepens cancer pipeline - +5.0 Summit Therapeutics Rises as Investors Continue to Digest AstraZeneca Deal
AstraZeneca deal with Summit drawing investor attention - +5.0 Summit Therapeutics Stock Has The Bull Case Changed After AstraZeneca Backing
AstraZeneca backing of Summit seen as supportive
Wednesday 7 October 2026
Reports cover AstraZeneca completing its $2bn Summit investment and the CEO's comments on ivonescimab combos.
- +6.7 AstraZeneca stock gets a USD 2 billion Summit oncology catalyst
$2bn Summit oncology investment seen as catalyst - +6.7 AstraZeneca completes $2 billion Summit investment. AstraZeneca stock gains 1.56 percent
Completes $2bn Summit investment, shares rise - +5.0 AstraZeneca CEO Pascal Soriot on Summit ivonescimab combos
CEO discusses Summit ivonescimab combinations - +5.0 Why Is AstraZeneca (LSE:AZN) Stock In Focus This Week After Its Summit Therapeutics Stake?
Summit stake puts shares in focus
Tuesday 6 October 2026
Outlets report AstraZeneca completing a $2bn equity investment in Summit.
- +6.7 AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
CEO sees Summit drug driving cancer combinations - +6.7 AstraZeneca expands oncology strategy with Summit drug collaboration and Cambridge R&D hub
Expands oncology strategy via Summit and R&D hub - +6.3 AstraZeneca Completes $2 Billion Investment in Summit Therapeutics
Completes $2bn investment in Summit for cancer drug - +6.3 AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Completes $2bn equity investment in Summit - +6.3 AstraZeneca invests $2B in Summit Therapeutics to advance next-gen cancer drug ivonescimab.
$2bn Summit investment for next-gen cancer drug - +6.3 AstraZeneca completes $2B equity investment in Summit Therapeutics
Completes $2bn equity investment in Summit - +5.8 AstraZeneca expands Summit collaboration
Expands Summit collaboration
Monday 5 October 2026
Summit, AstraZeneca and Daiichi plan a Phase III trial in triple-negative breast cancer.
- +6.3 Summit, AstraZeneca and Daiichi Sankyo Plan Phase III Trial in Triple-Negative Breast Cancer
Planned phase III trial in breast cancer with partners shows pipeline progress.
Sunday 4 October 2026
Outlets report AstraZeneca, Daiichi Sankyo and Summit teaming up to test a cancer drug combination.
- +7.0 AstraZeneca, Daiichi Sankyo & Summit team up to test cancer drug combination
Partnership to test cancer drug combination supports oncology pipeline. - +5.0 Summit Therapeutics (SMMT) Teams Up With AstraZeneca And Daiichi Sankyo, Is It 43% Undervalued?
Collaboration with Summit involving AstraZeneca; mildly positive pipeline news. - +4.2 AstraZeneca agrees to invest in Summit as AstraZeneca stock costs EUR 139.63
Agrees to invest in Summit; share price quoted.
Saturday 3 October 2026
AstraZeneca, Daiichi Sankyo and Summit announced a trial collaboration combining Datroway with ivonescimab, alongside AZ's $2bn Summit investment.
- +8.3 Summit Deal Could Help Futureproof AstraZeneca’s Datroway
Deal seen as helping extend Datroway's future - +8.3 AstraZeneca invests $2bn in Summit Therapeutics, deepening oncology ADC-bispecific ties
$2bn investment deepens oncology ADC-bispecific position - +7.5 Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
AstraZeneca's $2bn partnership with Summit announced - +7.5 AstraZeneca, Daiichi Sankyo Team With Summit on Triple-Negative Breast Cancer Trial
Trial collaboration in triple-negative breast cancer - +7.5 AstraZeneca PLC, Daiichi Sankyo And Summit Therapeutics Inc. Announce Clinical Collaboration To Evaluate Datroway In Combination With Ivonescimab Across Multiple Tumour Types
Clinical collaboration to test Datroway combination - +7.0 AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
Deepened Summit ties for ADC-bispecific combo testing - +7.0 AstraZeneca, Daiichi Sankyo, and Summit to Combine Datroway, Ivonescimab
Datroway and ivonescimab combination collaboration - +7.0 AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
Expands cancer push through Summit partnership - +7.0 AstraZeneca et Daiichi Sankyo s'associent à Summit pour tester une association de médicaments anticancéreux
Partnership to test cancer drug combination - +7.0 AstraZeneca, Daiichi team with Summit to pair Datroway with ivonescimab in Phase III TNBC push
Phase III TNBC push pairing Datroway with ivonescimab - +6.7 AstraZeneca and Daiichi Sankyo Team With Summit on Datroway Combination Trials
Datroway combination trials with Summit and Daiichi - +6.7 Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy
Combination therapy evaluation with Daiichi Sankyo - +6.7 AstraZeneca, Daiichi Sankyo partner with Summit to test Datroway-ivonescimab combinations
Partnership to test Datroway-ivonescimab combinations - +6.3 Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
Summit partnership with AstraZeneca and Daiichi - +6.3 AstraZeneca and Daiichi add Datroway to Summit cancer collab
Datroway added to Summit cancer collaboration - +6.3 Lung and breast cancers are targets of AstraZeneca (AZN)'s new three-company trial collaboration.
Lung and breast cancer trial collaboration - +6.3 Summit Therapeutics to test ivonescimab with AstraZeneca-Daiichi ADC
Ivonescimab to be tested with AstraZeneca-Daiichi ADC - +6.3 Summit Therapeutics plans Phase III Datroway breast cancer trial
Planned Phase III Datroway breast cancer trial - +6.3 Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo
Trial collaboration with AstraZeneca and Daiichi Sankyo - +5.8 Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS
AZ's $2bn bet on ivonescimab highlighted - +5.8 AstraZeneca invests USD 2.00 billion and AstraZeneca stock costs EUR 141.25
$2bn investment reported alongside share price - +5.8 SMMT Stock Gets Another Catalyst: Summit, AstraZeneca, Daiichi Sankyo Expand Cancer Drug Push
Expanded cancer drug push with Summit and Daiichi - +5.0 Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
Roundup including AstraZeneca collaboration with Summit - +5.0 Sam Fazeli: AstraZeneca's $2 Billion Summit Bet Tests Whether Strategics See What Public Markets Can't
Commentary on AstraZeneca's strategic $2bn Summit bet - +5.0 Innovation roundup: Carnegie Mellon in Miami, AstraZeneca's $2B investment
Roundup featuring AstraZeneca's $2bn investment - +5.0 Details on Datroway and Ivonescimab Collaboration and Development
Details of Datroway and ivonescimab collaboration - +1.7 AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3
Shares slightly lower despite Phase 3 combination progress
Friday 2 October 2026
Outlets report AstraZeneca's $2bn Summit investment and a related ivonescimab trial collaboration.
- +5.3 Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Clinical trial collaboration involving its Datroway ADC; pipeline expansion. - +5.0 AstraZeneca and two partners plan to test a cancer-drug pairing in breast cancer
Collaboration to test cancer-drug combination in breast cancer; pipeline progress.} - −3.7 AstraZeneca Stocks Drops as $2 Billion Buys an Oncology Option
Shares dropped as $2bn buys only an option. - −3.3 AstraZeneca invests USD 2 billion in Summit. AstraZeneca stock falls 1.24 percent.
Shares fall after $2bn Summit investment. - +3.0 AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up
$2bn investment in Summit gives oncology option; strategic but costly. - +2.5 AstraZeneca acquires stake in Summit Therapeutics for $2 billion
Reports $2bn stake acquisition in Summit. - +1.7 What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?
Focus on Summit's gain; AstraZeneca a named partner. - +1.7 Friday Five: Sanofi and Regeneron (re)partner up in the face of Dupixent's patent cliff, AstraZeneca invests $2B in Summit, Lilly delivers more weight loss wins…and more
Summit investment mentioned in weekly roundup among other stories. - +1.3 Why Is AstraZeneca (LSE:AZN) Stock In Focus Today After Its Summit Therapeutics Investment?
Stock in focus after Summit investment; neutral-ish coverage.
Thursday 1 October 2026
Coverage reports AstraZeneca's $2bn Summit investment and broker and market reaction.
- +9.2 Brokers applaud AstraZeneca's $2bn Summit bet
Brokers positive on the Summit investment - +8.3 AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
$2bn investment and collaboration in cancer drugs, strategic pipeline expansion - +7.5 AstraZeneca commits $2bn to advance ADC combination medicines for cancer
$2bn commitment to cancer combination medicines - +7.5 Why Did AstraZeneca (LSE:AZN) Lead FTSE 100 Healthcare Higher After Its Big Bet On Summit Therapeutics?
Led FTSE 100 healthcare higher after Summit deal - +6.7 AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck
Big deal to compete with rivals in cancer - +5.8 SMMT climbs nearly 5% after AstraZeneca funds cancer drug development
Funding of cancer development, focus on Summit gain - +5.8 Summit Therapeutics Soars on AstraZeneca Mega Deal
Mega deal coverage, mainly Summit's gain - +5.0 AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
Deal framed as vote of confidence - +5.0 AstraZeneca stock tracks a USD 2.0 billion cancer deal
Share price tracking the cancer deal
Wednesday 30 September 2026
AstraZeneca made a $2bn equity investment in Summit to back ivonescimab.
- +7.5 AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says
UBS calls the investment win-win. - +5.8 AstraZeneca boards the PD-1/VEGF ship with $2B Summit investment
AstraZeneca enters PD-1/VEGF space with $2B investment. - +5.0 AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
Reports AstraZeneca's equity investment in Summit; strategic oncology move. - +5.0 AstraZeneca takes a £1.5bn stake in US cancer drug developer as it steps up investment in America
Stake in US cancer developer, stepping up US investment. - +5.0 AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Strategic $2B equity investment in Summit. - +5.0 Astrazeneca invests $2B in Summit for bispecific/ADC combos
$2B investment in Summit for bispecific/ADC combinations. - +5.0 AstraZeneca bets $2 billion on Summit’s cancer drug in major ADC push
$2B bet on Summit drug as oncology push. - +4.2 AstraZeneca pours $2bn into Summit to advance cancer treatment
$2bn into Summit to advance cancer treatment. - +4.2 Key facts: Mid-Nov U.S. decision on ivonescimab; AstraZeneca (AZN) up
Upcoming US decision on ivonescimab; AstraZeneca shares up. - +4.2 Key facts: SMMT Seeks Financing; Shares Jump on AstraZeneca Pact
Summit pact with AstraZeneca reported; AstraZeneca a named party. - +4.2 Vital Signs: AstraZeneca's $2B seat at Summit's table
AstraZeneca takes $2B stake in Summit. - +4.2 Novo Nordisk and AstraZeneca Announce Licensing Deals Totaling $4.6 Billion
AstraZeneca licensing deal announced as part of $4.6B combined. - +4.2 Novo Nordisk Licenses Hengrui Pharma’s HRS-1596 and AstraZeneca Partners with Summit Therapeutics in $2 Billion Oncology Deal
AstraZeneca partners with Summit in $2B oncology deal. - −4.2 A $2 Billion Reason Why AstraZeneca Stock Is Down Today
Stock down on the day due to $2B deal. - +3.3 AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug
$2B bet on Summit cancer drug. - +3.3 Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal
Analyst note on Summit after AstraZeneca deal; mildly supportive. - +3.3 AstraZeneca Backing Could Change The Case For Summit Therapeutics Stock
AstraZeneca backing seen as positive for Summit case. - +3.3 AstraZeneca Pays $2 Billion To Take On Pfizer, Merck, Bristol
Pays $2B to compete with big pharma rivals. - +3.3 Novo Nordisk and AstraZeneca Announce $4.6 Billion in Combined Pharmaceutical Licensing Deals
AstraZeneca licensing deal announced alongside Novo. - +3.3 Novo Nordisk and AstraZeneca Announce Licensing Deals with Hengrui Pharma and Summit Therapeutics
AstraZeneca licensing deal with Summit announced. - +3.3 SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet
AstraZeneca backs ivonescimab bet. - +3.3 Summit Therapeutics Rises as AstraZeneca Backs Ivonescimab With $2 Billion Investment
Summit rises on AstraZeneca's backing. - +3.3 Paolo Tarantino: AstraZeneca Repeats Its Asia-Developed Drug Bet
AstraZeneca repeats Asia-developed drug bet. - +3.3 Will AstraZeneca stock hold support as Summit Therapeutics partnership expands oncology pipeline?
Partnership expands oncology pipeline; share support questioned. - +2.5 SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare?
Focus on Summit, but AstraZeneca funding is the catalyst. - +0.8 FTSE 100 today: Stocks fall as shop prices slow; AstraZeneca buys Summit stake
FTSE report notes Summit stake amid falling market.